2024
Preemptive Kidney Transplantation Trends in Lupus
Contreras G, Pagan J, Elfassy T, Bandes M, Bustamante N, Goggins M, Becerra L, Mendoza J, Drexler Y, Alonso S, Roth D. Preemptive Kidney Transplantation Trends in Lupus. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024p18r0q9c. DOI: 10.1681/asn.2024p18r0q9c.Peer-Reviewed Original ResearchInfluenza B Triggering Atypical Hemolytic Uremic Syndrome (aHUS) in a Patient with Cobalamin C (CblC) Disease Carrier State and a Complement Factor H (CFH) Mutation
Becerra L, Moeckel G, Gunasekaran D. Influenza B Triggering Atypical Hemolytic Uremic Syndrome (aHUS) in a Patient with Cobalamin C (CblC) Disease Carrier State and a Complement Factor H (CFH) Mutation. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024vajywpws. DOI: 10.1681/asn.2024vajywpws.Peer-Reviewed Original ResearchMinimal Change Disease (MCD) and Human Chorionic Gonadotropin (hCG)-Mediated Thyrotoxicosis during Pregnancy
Becerra L, Moeckel G, Gondal M. Minimal Change Disease (MCD) and Human Chorionic Gonadotropin (hCG)-Mediated Thyrotoxicosis during Pregnancy. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024f2jtc080. DOI: 10.1681/asn.2024f2jtc080.Peer-Reviewed Original ResearchWCN24-330 TRENDS OF PREEMPTIVE KIDNEY TRANSPLANTATION IN PATIENTS APPROACHING END-STAGE RENAL DISEASE STRATIFIED BY PRIMARY DISEASE IN THE UNITED STATES FROM 1985 AND 2019
Martin G, Pagan J, Bustamante N, Ortigosa-Goggins M, Bandes M, Elfassy T, Becerra L, Mendoza J, Morales E, Drexler Y, Kupin W, Roth D. WCN24-330 TRENDS OF PREEMPTIVE KIDNEY TRANSPLANTATION IN PATIENTS APPROACHING END-STAGE RENAL DISEASE STRATIFIED BY PRIMARY DISEASE IN THE UNITED STATES FROM 1985 AND 2019. Kidney International Reports 2024, 9: s442-s443. DOI: 10.1016/j.ekir.2024.02.929.Peer-Reviewed Original ResearchEffects of Empagliflozin on the Progression of Chronic Kidney Disease
Aponte Becerra L, Turner JM. A commentary on: Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. PracticeUpdate website.Commentaries, Editorials and Letters
2023
Relationships among Non-Neoplastic Histopathological Features, Kidney Function, Proteinuria, and Other Clinical Factors in Patients Undergoing Nephrectomy
Becerra L, Betancourt J, Elfassy T, Iakymenko O, Thomas D, Isaac F, Fornoni A, Zuo Y, Barisoni L, Contreras G, Mendoza J. Relationships among Non-Neoplastic Histopathological Features, Kidney Function, Proteinuria, and Other Clinical Factors in Patients Undergoing Nephrectomy. Glomerular Diseases 2023, 3: 220-229. PMID: 37915860, PMCID: PMC10616670, DOI: 10.1159/000534339.Peer-Reviewed Original ResearchLower eGFRGlobal glomerulosclerosisInterstitial fibrosisCardiovascular diseaseClinical factorsHistopathological featuresSpecific histopathological featuresGlomerular filtration rateCross-sectional analysisDipstick proteinuriaKidney functionMultivariable analysisFiltration rateKidney parenchymaOutcome measuresProteinuriaRoutine examinationHypertensionPatientsArteriosclerosisEGFRNephrectomyObesityAssociationRegression modelsDaily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up
Becerra L, Gavrieli A, Khan F, Novak P, Lioutas V, Ngo L, Novak V, Mantzoros C. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up. Clinical Nutrition 2023, 42: 825-834. PMID: 37084469, PMCID: PMC10330069, DOI: 10.1016/j.clnu.2023.04.008.Peer-Reviewed Original ResearchConceptsBody mass indexType 2 diabetesIntranasal insulinSecondary outcomesFood intakeBody compositionType 2 diabetes trialsOlder adultsPlacebo-controlled studyPlacebo-controlled trialDiabetes (ACCORD) trialPrimary outcomeIntervention visitsMass indexBody fatAnthropometric measuresAnimal studiesBody weightHigh dosesInteraction of treatmentEnergy homeostasisDiabetesInsulinWeight lossAppetiteOne-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis.
Munoz Mendoza J, Aponte-Becerra L, Torres C, Rozas J, Francois P, Salcedo J, Barreto A, Rodriguez J, Suarez M, Fornoni A, Contreras G. One-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis. Clinical Nephrology 2023, 99: 51-57. PMID: 36519940, DOI: 10.5414/cn110823.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseCOVID-19 infectionLong-term mortality riskHospital mortalityMortality riskRenal diseaseOdds ratioCOVID-19Higher long-term mortality riskRetrospective chart reviewAdjusted odds ratioLogistic regression modelsESRD patientsCause mortalitySecondary outcomesChart reviewPrimary outcomeHospitalized patientsHigher oddsMortality ratePatientsMortalityOne-yearInfectionSignificant differences
2022
Depressive symptoms exacerbate disability in older adults: A prospective cohort analysis of participants in the MemAID trial
Buss S, Becerra L, Trevino J, Fortier C, Ngo L, Novak V. Depressive symptoms exacerbate disability in older adults: A prospective cohort analysis of participants in the MemAID trial. PLOS ONE 2022, 17: e0278319. PMID: 36445876, PMCID: PMC9707770, DOI: 10.1371/journal.pone.0278319.Peer-Reviewed Original ResearchConceptsDepressive symptomsImportant modifiable risk factorOlder adultsWeek 48 visitModifiable risk factorsProspective cohort analysisEffect of comorbiditySelf-reported disabilityType 2 diabetesGeriatric Depression ScalePublic health priorityIntranasal insulinMedical comorbiditiesCardiovascular mortalityGait speedRisk factorsClinical trialsNormal limitsWeek 25Depression ScaleHealth priorityCohort analysisComorbiditiesWorse cognitionCognitive declineSafety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
Aponte Becerra L, Galindo Mendez B, Khan F, Lioutas V, Novak P, Mantzoros C, Ngo L, Novak V. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial. Archives Of Diabetes & Obesity 2022, 4: 403-415. PMID: 35903156, PMCID: PMC9328174.Peer-Reviewed Original ResearchContinuous glucose monitoringIntranasal insulinGlycemic variabilitySystemic insulinAdverse eventsPlacebo treatmentHypoglycemic episodesWeight gainDouble-blinded placeboSerious adverse eventsDouble-blinded trialType 2 diabetesSubcutaneous insulinDiabetes burdenPlasma glucoseCapillary glucoseInsulin sensitivitySub studyLong-term effectsSafety outcomesTrial participantsGlucose metabolismShort-term effectsInsulinDiabetesMemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial
Novak V, Mantzoros C, Novak P, McGlinchey R, Dai W, Lioutas V, Buss S, Fortier C, Khan F, Aponte Becerra L, Ngo L. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. Journal Of Neurology 2022, 269: 4817-4835. PMID: 35482079, PMCID: PMC9046533, DOI: 10.1007/s00415-022-11119-6.Peer-Reviewed Original ResearchConceptsIntranasal insulinCerebral blood flowPlasma insulinBlood flowType 2 diabetes mellitusVerbal memorySerious adverse eventsDouble-blinded trialRandomized clinical trialsType 2 diabetesAge-related functional declineHOMA-IRAdverse eventsDiabetes mellitusPrimary outcomeWeeks treatmentHypoglycemic episodesT2DM participantsControl placeboPreliminary safetyClinical trialsFunctional declineLong-term effectsBackgroundThis studyBetter executive function
2021
Prevalence and Risk Factors Associated with Diabetic Nephropathy in Patients with Diabetes Undergoing Nephrectomy
Becerra L, Betancourt J, Fornoni A, Iakymenko O, Contreras G, Marin S, Rodriguez J, Mohsin N, Valencia O, Rodriguez A, Barisoni L, Thomas D, Mendoza J. Prevalence and Risk Factors Associated with Diabetic Nephropathy in Patients with Diabetes Undergoing Nephrectomy. Journal Of The American Society Of Nephrology 2021, 32: 274-274. DOI: 10.1681/asn.20213210s1274a.Peer-Reviewed Original ResearchIn-Hospital Mortality in Patients with ESRD Undergoing Hemodialysis Admitted with COVID-19 Compared to Those Without COVID-19
Becerra L, Rozas J, Torres C, Francois P, Rodriguez J, Betancourt J, Rodriguez A, Ortiz M, Fornoni A, Contreras G, Mendoza J. In-Hospital Mortality in Patients with ESRD Undergoing Hemodialysis Admitted with COVID-19 Compared to Those Without COVID-19. Journal Of The American Society Of Nephrology 2021, 32: 774-774. DOI: 10.1681/asn.20213210s1774b.Peer-Reviewed Original ResearchGlycemic variability of acute stroke patients and clinical outcomes: a continuous glucose monitoring study.
Palaiodimou L, Lioutas VA, Lambadiari V, Theodorou A, Themistocleous M, Aponte L, Papagiannopoulou G, Foska A, Bakola E, Quispe R, Mendez L, Selim M, Novak V, Tzavellas E, Halvatsiotis P, Voumvourakis K, Tsivgoulis G. Glycemic variability of acute stroke patients and clinical outcomes: a continuous glucose monitoring study. Ther Adv Neurol Disord 2021, 14: 17562864211045876. PMID: 34589140, DOI: 10.1177/17562864211045876.Peer-Reviewed Original ResearchDeep transfer learning and data augmentation improve glucose levels prediction in type 2 diabetes patients
Deng Y, Lu L, Aponte L, Angelidi A, Novak V, Karniadakis G, Mantzoros C. Deep transfer learning and data augmentation improve glucose levels prediction in type 2 diabetes patients. Npj Digital Medicine 2021, 4: 109. PMID: 34262114, PMCID: PMC8280162, DOI: 10.1038/s41746-021-00480-x.Peer-Reviewed Original ResearchData augmentationTransfer learningNetwork architectureData augmentation techniquesNeural network architectureTransfer-learning strategyDeep-learning methodsDeep learning modelsDeep transfer learningTransfer-learning methodsSame network architectureDifferent loss functionsFuture glucose levelsAccurate predictive modelsH prediction horizonPublic datasetsGenerative modelGlucose level predictionAugmentation techniquesLoss functionPrediction accuracyDatasetLevel predictionPrediction horizonArchitectureTilt Test: A Review.
Aponte-Becerra L, Novak P. Tilt Test: A Review. J Clin Neurophysiol 2021, 38: 279-286. PMID: 34009851, DOI: 10.1097/WNP.0000000000000625.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial
NOVAK V, MANTZOROS C, NOVAK P, MCGLINCHEY R, DAI W, LIOUTAS V, BUSS S, FORTIER C, KHAN F, BECERRA L, NGO L. 193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial. Diabetes 2021, 70 DOI: 10.2337/db21-193-or.Peer-Reviewed Original ResearchIntranasal insulinSpouse/partnerT2DM-related cognitive impairmentType 2 diabetes mellitusPhase 2 trialSignificant adverse eventsRisk of dementiaDual-task walkingNovo NordiskPseudo-continuous arterial spin labelingArterial spin labelingWorld Health OrganizationAdvisory PanelAdverse eventsDiabetes mellitusPrimary outcomeDual taskT2DM participantsKidney diseaseBlind trialControl trialDrug AdministrationType 2Cognitive impairmentT2DM718-P: Long-Term Safety of Intranasal Insulin (INI) in Insulin-Dependent Type 2 Diabetes (T2DM-IDDM): A Safety Substudy of Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Trial
BECERRA L, MENDEZ B, KHAN F, MANTZOROS C, NOVAK P, LIOUTAS V, NGO L, NOVAK V, TREVINO J. 718-P: Long-Term Safety of Intranasal Insulin (INI) in Insulin-Dependent Type 2 Diabetes (T2DM-IDDM): A Safety Substudy of Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Trial. Diabetes 2021, 70 DOI: 10.2337/db21-718-p.Peer-Reviewed Original ResearchIntranasal insulinSerious adverse eventsCapillary glucoseSpouse/partnerContinuous glucose monitoringPlacebo groupAdverse eventsSubcutaneous insulinInsulin-dependent type 2 diabetesType 2 diabetes trialsLevel 1 hypoglycemiaPlacebo-treated participantsWeeks of treatmentFuture larger studiesType 2 diabetesLevel 2 hypoglycemiaNovo NordiskWorld Health OrganizationAdvisory PanelDiabetes (ACCORD) trialConcomitant administrationInsulin levelsKidney diseaseFunctional declineTerm safety719-P: Caloric Intake, Appetite, and Body Composition Outcomes of Long-Term Intranasal Insulin (INI) Administration: A Substudy of the Memory Advancement by INI in Type 2 Diabetes (MemAID) Study
BECERRA L, KHAN F, NGO L, NOVAK V, MANTZOROS C, GAVRIELI A, UPADHYAY J. 719-P: Caloric Intake, Appetite, and Body Composition Outcomes of Long-Term Intranasal Insulin (INI) Administration: A Substudy of the Memory Advancement by INI in Type 2 Diabetes (MemAID) Study. Diabetes 2021, 70 DOI: 10.2337/db21-719-p.Peer-Reviewed Original ResearchType 2 diabetesSecondary outcomesSpouse/partnerCaloric intakeFood intakeAnthropometric measuresBody compositionIntranasal insulin administrationBody composition outcomesType 2 Diabetes StudyWeeks of treatmentNovo NordiskWorld Health OrganizationAdvisory PanelPrimary outcomeIntervention visitsInsulin resistanceKidney diseaseDiabetes StudyInsulin administrationBody fatBlind trialAnimal studiesComposition outcomesDrug Administration
2019
Continuous glucose monitoring in acute stroke
Aponte-Becerra L, Quispe R, Mendez-Pino L, Novak V, Selim M, Lioutas V. Continuous glucose monitoring in acute stroke. 2019, 90-95. DOI: 10.46354/i3m.2019.iwish.016.Peer-Reviewed Original ResearchAcute strokeContinuous glucose monitoringGlycaemic variabilityAssociated with poor clinical outcomesAmplitude of glucose excursionAcute stroke settingAssociated with high mortality ratesPoor clinical outcomesStroke patientsGlucose monitoringAcute brain ischemiaStroke settingPilot studyHigher mortality rateClinical outcomesPoor prognosisMortality rateCoefficient of variationHypoglycaemic episodesGlucose excursionsBrain ischemiaMonitoring regimenStrokeCompare continuous glucose monitoring